Heron Therapeutics Inc (NASDAQ:HRTX) VP Kimberly Manhard sold 1,109 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $18.86, for a total transaction of $20,915.74. Following the sale, the vice president now owns 1,109 shares of the company’s stock, valued at approximately $20,915.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of HRTX traded up $0.10 during trading hours on Thursday, hitting $17.85. The company’s stock had a trading volume of 3,877,776 shares, compared to its average volume of 1,066,362. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -7.32 and a beta of 1.46. Heron Therapeutics Inc has a 52-week low of $16.20 and a 52-week high of $42.90.
Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Friday, February 22nd. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.17). The business had revenue of $28.84 million during the quarter, compared to analysts’ expectations of $28.05 million. Heron Therapeutics had a negative return on equity of 54.98% and a negative net margin of 230.84%. On average, research analysts expect that Heron Therapeutics Inc will post -1.55 earnings per share for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Heron Therapeutics by 36.7% in the third quarter. Vanguard Group Inc. now owns 6,193,249 shares of the biotechnology company’s stock worth $196,016,000 after purchasing an additional 1,661,318 shares in the last quarter. Vanguard Group Inc boosted its position in shares of Heron Therapeutics by 36.7% in the third quarter. Vanguard Group Inc now owns 6,193,249 shares of the biotechnology company’s stock valued at $196,016,000 after acquiring an additional 1,661,318 shares during the period. BlackRock Inc. boosted its position in shares of Heron Therapeutics by 2.8% in the fourth quarter. BlackRock Inc. now owns 4,913,006 shares of the biotechnology company’s stock valued at $127,443,000 after acquiring an additional 132,207 shares during the period. D. E. Shaw & Co. Inc. boosted its position in shares of Heron Therapeutics by 81.4% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,054,008 shares of the biotechnology company’s stock valued at $27,341,000 after acquiring an additional 473,127 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Heron Therapeutics by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 751,250 shares of the biotechnology company’s stock valued at $19,487,000 after acquiring an additional 26,429 shares during the period.
A number of research firms recently issued reports on HRTX. BidaskClub downgraded shares of Heron Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, April 18th. Zacks Investment Research downgraded shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 9th. ValuEngine downgraded shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $38.00 target price on shares of Heron Therapeutics in a research note on Wednesday. Three analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. Heron Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $51.20.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Article: What are the risks of holding treasury bonds?
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.